908 Devices (MASS) Leerink Global Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Leerink Global Healthcare Conference 2026 summary
9 Mar, 2026Market drivers and macro environment
Demand is driven by illicit drug crises, toxic industrial chemicals, and global unrest, with conflicts like Ukraine and Middle East tensions increasing customer prioritization for modernization and preparedness.
NATO countries are increasing defense spending targets to 5% of GDP by 2035, supporting a rising tide in customer demand.
International revenues grew from 25% to 27% of total, with ambitions to reach 40-50% as global demand rises.
No immediate impact from inflation or oil prices, as most funding is grant-based and already allocated.
U.S. government funding remains robust, with 11 of 12 appropriations bills passed and multi-year grants supporting state and local customers.
Financial performance and outlook
Achieved 21% revenue growth in Q4, surpassing guidance, with state and local customers contributing 43% of annual revenue.
Guidance for 2026 targets 15-20% annual growth, with Q1 expected to be slower due to product restocking and typical seasonality.
Adjusted EBITDA turned positive in Q4 ($700K), with a path to full-year profitability by 2027 as growth and margin improvements continue.
Gross margin expected to expand by 100 basis points, driven by insourcing, Danbury consolidation, and product mix.
Recurring revenue rose 22% year-over-year, now 35% of total, with further growth expected from software and OEM channels.
Product innovation and pipeline
Next-gen MX908 handheld mass spectrometer to be announced later this year, targeting both replacement and expansion opportunities.
VipIR and XplorIR products showed strong traction, with over 40 and 150 installs respectively, and are expected to drive growth in new and existing accounts.
AVCAD OEM program with Smiths Detection expected to ramp from $2-3 million in 2026 to potentially $10 million annually over 5-7 years.
Product development focuses on reducing size, weight, and complexity, responding to customer feedback for simplicity and ease of use.
Team Leader software and expanded portfolio aim to increase recurring revenue and market penetration.
Latest events from 908 Devices
- Transformation and innovation in handheld detection devices drive strong growth and profitability.MASS
Sidoti March Small-Cap Virtual Conference18 Mar 2026 - Up to $100 million in securities to fund growth in handheld chemical analysis markets.MASS
Registration Filing9 Mar 2026 - Handheld detection tools, new products, and software drive growth and recurring revenue in 2026.MASS
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - 2025 revenue rose 18% to $56.2M, margins hit 57%, and Q4 Adjusted EBITDA turned positive.MASS
Q4 20253 Mar 2026 - Q2 revenue up 16% to $14M; 2024 outlook reaffirmed at $63–$65M, with strong handheld growth.MASS
Q2 20242 Feb 2026 - Handheld growth, RedWave integration, and innovation set the stage for future acceleration.MASS
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - RedWave acquisition and product innovation drive growth, margin gains, and market expansion.MASS
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - Q3 revenue up 17%, but net loss widened on goodwill impairment and RedWave acquisition costs.MASS
Q3 202415 Jan 2026 - Portfolio expansion, RedWave synergies, and operational changes position for growth in 2025.MASS
Stifel 2024 Healthcare Conference13 Jan 2026